March 18, 2022

Team Reconstructs Sternum, Sternoclavicular Joints with a Cadaveric Femur, Aortograft and Ankle-Fixation Cord

Innovative construct restores function after resection of softball-size chondrosarcoma

22-ORI-2662859 CQD 650x450b

By Nathan Mesko, MD, and Daniel Raymond, MD


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A 59-year-old patient presented with a 14-centimeter tumor on his sternum. He noticed the lump after a motor vehicle accident 13 years earlier. Over the years he had been told that the lesion was benign, but it had continued to grow larger than the size of a softball. CT imaging of the tumor detected characteristics of a bone lesion containing cartilage, a concerning finding in an adult, whose growth plates have long been closed. Needle biopsy revealed a chondrosarcoma diagnosis.

X-ray showing a large ball growing from the sternum
CT imaging showed a cartilage tumor expanding the sternum, suspicious for a chondrosarcoma. This was later proven following a biopsy procedure.

Chondrosarcoma is the most common bone sarcoma in adults and the third most common bone sarcoma in humans, after osteosarcoma and Ewing sarcoma, which are more prevalent in younger populations. There is a spectrum of chondrosarcoma subtypes, some indolent (like this case) and some aggressive. More aggressive subtypes have significant prognostic implications, with survival lasting potentially just a few months. Chondrosarcoma tumors rarely respond to chemotherapy or radiation therapy, so treatment typically is resection alone.

Even if the tumor in this case had been benign, it still would have required resection as it had begun to compress the trachea, the esophagus and the left carotid artery.

The tumor did not appear to involve deeper thoracic structures, however its removal would be a formidable challenge. Along with most of the sternum, both sternoclavicular joints — the only skeletal attachment between the arms and axial skeleton — would need to be resected and then reconstructed.

Planning for a challenging reconstruction

Reconstructing the sternum is critical for protecting the heart and other thoracic organs, for recreating anterior support for the spine (to prevent kyphosis) and for providing an anchor for arm mobility. However, because removal of the sternum and sternoclavicular joints is so rare, reconstruction requires a novel approach that balances the need for stable fixation with allowances for subtle motion. There are only limited descriptions of this type of reconstruction in medical literature. There is no established standard of care, and artificial implants do not exist.


Typical reconstruction techniques using plates and screws or other fixation devices are not appropriate for sternoclavicular anatomy as this anatomic location must accommodate motion when arms are moved or lifted, or when breathing expands and contracts the chest. In this case, the challenge was to recreate chest wall anatomy while permitting mobility.

Thoracic and orthopaedic surgeons collaborated to design a new construct using a cadaveric femur in place of a sternum. The femur would be suspended from both clavicles using a combination of technologies including a synthetic aortograft (a flexible but tough polyethylene tube used to treat aortic aneurysms), polyethylene terephthalatesuture and Syndesmosis TightRope® (Arthrex) fixation (a polyethylene cord used for ankle stabilization).

Before the construct could be built and the surgical procedure attempted, an appropriately sized femur would be obtained from a bone bank.

Resection and reconstruction, step by step

During the procedure, the thoracic surgeon removed the tumor and sternum while the orthopaedic surgeon fashioned the new construct. The cadaveric femur was anchored to the remaining sternum via a scarf joint, secured with sutures. To build the sternoclavicular joints, the TightRope fixation devices first were placed to anchor the sternum to the clavicles. The aortograft, which had been affixed to the femur with cables, was wound around the cut ends of the clavicles and anchored with additional cables. Finally, polyester sutures were woven between the clavicles by means of a cannulated screw in the femur. The construct was covered with mesh, which would prevent lung herniation in the small lateral defects as well as provide an additional layer of support.

Clamp holding a white bone with a rod through it
A femoral allograft was obtained from a national bone bank and prepared to fit the sternal defect.
Bone with white material and cables wrapped around it
After the femoral allograft was fashioned to planned specifications, it was overwrapped with a synthetic aortic graft and fixated with a combination of cables, cannulated screws, ultrahigh-molecular-weight polyethylene core suture and polyethylene terephthalate tape.
The bone with cables wrapped around it being slid under the skin of the chest
The reconstructed allograft implant was inserted into the sternal defect, using the scarf joint to slide under the remaining lower (distal) part of the native sternum bone.
The open chest with the new sternum in place
The completed reconstruction was suspended between the clavicles using a suspensory technique involving a mechanism normally used for fixing ankle fractures and high ankle sprains. The aortograft material was wrapped around the clavicles and further supplemented with polyethylene terephthalate tape suspension.
X-ray of the chest showing the ribs and sternum
A chest X-ray shows the final sternal reconstruction.


Three months after surgery, the patient is pain-free and back to work. He has been advised to avoid heavy lifting. He will be followed closely and watched for scoliosis and any change that may affect the construct, especially once he is able to lift his arms above 90 degrees. Scar tissue will further anchor the construct.


Due to the clean resection of the chondrosarcoma, the patient is expected to have a normal life span. For chondrosarcoma in general, survival is 70-75% at five years. With nonaggressive chondrosarcoma, as in this case, survival can be 99% at five years.

A synergy of thoracic and orthopaedic surgery

This case highlights a novel approach to reconstructing a challenging anatomic site. Existing alternatives, such as 3D-printed anatomy and other custom-built implants, would require a lengthy approval process not preferable for a patient with cancer. In addition, even custom implants cannot readily solve the dilemma of balancing the need for motion with durable fixation and reconstruction. The cadaveric femur construct, incorporating an aortograft and ankle-fixation mechanism, leverages technologies readily available and provides durable fixation with robust materials while allowing for motion as needed.

The construct also showcases the synergy of skill sets required to develop innovative solutions for challenging cases. In this case, the collaboration of thoracic and orthopaedic surgery experts led to a unique approach — combining a cadaver bone, cardiovascular technology and an ankle suspension mechanism — that never would have evolved without multidisciplinary teamwork.

Dr. Mesko is Center Director, Orthopaedic Oncology, and co-Director of Sarcoma Care at Cleveland Clinic. Dr. Raymond is a thoracic surgeon in the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.

Related Articles

23-HVI-3529770 CQD 650×450
March 23, 2023
Massive Spine and Retroperitoneal Sarcoma: A Case Study in Surgical Collaboration

Invasion of the lumbar spine and iliac vein made resection risky

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival